Credit Suisse analyst Andrew Kuske upgrades Algonquin Power (NYSE:AQN) from Neutral to Outperform.
Following Granting Of Indian Patent, Indaptus Therapeutics Achieves Patent Protection In 32 Countries For Decoy Immunotherapy Platform
Indaptus Therapeutics, Inc. (NASDAQ:INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it has received notice of allowance for a disease